|
|
|
|
|
by skeledrew
34 days ago
|
|
If it isn't a potentially big money-maker said big incumbent won't touch it though. Will more likely try to shut it down especially if it overlaps with any of their more ludicrous offerings. And given the properties that this has (easy to manufacture, stable, soluble, low/no toxicity, etc) it's ripe for a shutdown because it'd make AD treatments far too cheap. |
|